San Diego Xconomy editor Bruce Bigelow discusses the CureMatch product launch and CEO Blaise Barrelet’s personal cancer story.
A study of 136 patients with advanced cancers performed by UCSD oncologist and CureMatch co-founder Dr. Razelle Kurzrock and colleagues suggested that combination therapy may be more efficacious than single-drug therapy.
OncoImmunology Publication Validates Need to Determine Specific Subset of Mutations that Elicit Cancer Therapy Response SAN DIEGO, CA – February 7, 2017 – CureMatch, the developer of a Decision Support System for combination therapy in cancer, today revealed in the peer-reviewed journal OncoImmunology the description of a specific mechanism that can potentially be used for selecting […]
Clinical Research Currents today featured CureMatch co-founders Igor Tsigelny, Ph.D. and Razelle Kurzrock, M.D., and discussed CureMatch’s new decision support system.
A multi-year study was performed by UCSD oncologist and CureMatch co-founder Dr. Razelle Kurzrock and colleagues, and looked at 291 patients with advanced cancers, who had received either the standard of care (n = 116) or personalized cancer therapy (n = 175). Patients treated using the standard of care, which was based on their type of cancer, had […]
